Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure.
J. Shan
No relevant relationships to disclose
S. M. O'Brien
No relevant relationships to disclose
G. Garcia-Manero
No relevant relationships to disclose
S. Faderl
No relevant relationships to disclose
F. Ravandi
Honoraria - Eisai; Johnson & Johnson
Research Funding - Eisai
E. Jabbour
Honoraria - Bristol-Myers Squibb; Novartis
J. E. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
H. Kantarjian
Consultant or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer